US5180589A
(en)
*
|
1988-03-31 |
1993-01-19 |
E. R. Squibb & Sons, Inc. |
Pravastatin pharmaceuatical compositions having good stability
|
GR1002098B
(en)
*
|
1989-06-08 |
1995-12-28 |
Squibb & Sons Inc |
Pharmaceutical composition having good stability
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
HU221849B1
(hu)
*
|
1991-12-12 |
2003-02-28 |
Novartis Ag. |
HMG-CoA reduktáz inhibitor fluvasztatint tartalmazó stabilizált gyógyszerkészítmények
|
HU9203780D0
(en)
*
|
1991-12-12 |
1993-03-29 |
Sandoz Ag |
Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
|
EP0680320B1
(de)
*
|
1993-01-19 |
1999-04-14 |
Warner-Lambert Company |
Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
|
US5506248A
(en)
*
|
1993-08-02 |
1996-04-09 |
Bristol-Myers Squibb Company |
Pharmaceutical compositions having good dissolution properties
|
JP4105762B2
(ja)
|
1995-02-28 |
2008-06-25 |
アベンティス・ファーマスーティカルズ・インコーポレイテツド |
ピペリジノアルカノール化合物のための医薬組成物
|
PL186907B1
(pl)
*
|
1995-12-22 |
2004-03-31 |
Kowa Co |
Kompozycja farmaceutyczna stabilizowana czynnikiem zasadowym
|
EP0839526A3
(de)
|
1996-10-31 |
1999-01-07 |
Takeda Chemical Industries, Ltd. |
Festes pharmazeutisches Präparat mit schneller Auflösungs- oder Disintegrationeigenschaften
|
DE19724123A1
(de)
|
1997-06-09 |
1998-12-10 |
Voith Sulzer Papiermasch Gmbh |
Vorrichtung und Verfahren zum Überführen eines Einfädelstreifens oder einer Materialbahn
|
US6147109A
(en)
*
|
1997-10-14 |
2000-11-14 |
The General Hospital Corporation |
Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
|
JP2001526234A
(ja)
*
|
1997-12-22 |
2001-12-18 |
シェーリング コーポレイション |
経口投与が可能な固形リバビリン投薬の形態およびそれらの製造プロセス
|
US5916594A
(en)
*
|
1997-12-22 |
1999-06-29 |
Schering Corporation |
Process of making solid ribavirin dosage forms
|
US5914128A
(en)
*
|
1997-12-22 |
1999-06-22 |
Schering Corporation |
Orally administrable solid dosage form
|
US6180597B1
(en)
|
1998-03-19 |
2001-01-30 |
Brigham And Women's Hospital, Inc. |
Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
|
KR100281521B1
(ko)
*
|
1998-03-31 |
2001-02-15 |
김종인 |
프라바스타틴나트륨이 함유된 약제 조성물
|
ES2274625T3
(es)
|
1998-05-18 |
2007-05-16 |
Takeda Pharmaceutical Company Limited |
Comprimidos desintegrables en la boca que comprenden un bencimidazol.
|
US6232351B1
(en)
*
|
1998-05-22 |
2001-05-15 |
Amway Corporation |
Co-processed botanical plant composition
|
US6423751B1
(en)
|
1998-07-14 |
2002-07-23 |
The Brigham And Women's Hospital, Inc. |
Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
|
AU4802099A
(en)
|
1998-07-28 |
2000-02-21 |
Takeda Chemical Industries Ltd. |
Rapidly disintegrable solid preparation
|
US5985907A
(en)
*
|
1998-08-12 |
1999-11-16 |
Health Research, Inc. |
Method for inhibiting growth of methanogens
|
SI20109A
(sl)
*
|
1998-12-16 |
2000-06-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Stabilna farmacevtska formulacija
|
US6838091B2
(en)
|
1998-12-18 |
2005-01-04 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6391583B1
(en)
|
1998-12-18 |
2002-05-21 |
Wisconsin Alumni Research Foundation |
Method of producing antihypercholesterolemic agents
|
US6814977B1
(en)
|
1998-12-18 |
2004-11-09 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US7014864B1
(en)
|
1998-12-18 |
2006-03-21 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6569461B1
(en)
|
1999-03-08 |
2003-05-27 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
|
WO2000057918A2
(en)
*
|
1999-03-31 |
2000-10-05 |
Abbott Laboratories |
Novel formulations comprising lipid-regulating agents
|
US6719999B2
(en)
|
1999-03-31 |
2004-04-13 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6465011B2
(en)
|
1999-05-29 |
2002-10-15 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6372251B2
(en)
|
1999-06-11 |
2002-04-16 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
GB0001621D0
(en)
*
|
2000-01-26 |
2000-03-15 |
Astrazeneca Ab |
Pharmaceutical compositions
|
USRE44578E1
(en)
|
2000-04-10 |
2013-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
|
ES2401598T3
(es)
*
|
2000-04-10 |
2013-04-22 |
Teva Pharmaceutical Industries, Ltd. |
Composiciones farmacéuticas estables que contienen ácidos 7-sustituido-3,5-dihidroxiheptanoicos o ácidos 7-sustituido-3,5-dihidroxiheptenoicos
|
US6242003B1
(en)
|
2000-04-13 |
2001-06-05 |
Novartis Ag |
Organic compounds
|
SI1292293T1
(en)
|
2000-06-09 |
2004-06-30 |
LEK farmacevtska dru�ba d.d. |
Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
|
WO2001093859A1
(en)
|
2000-06-09 |
2001-12-13 |
Lek Pharmaceuticals D.D. |
Stable pharmaceutical product and formulation
|
US6806290B2
(en)
|
2000-06-09 |
2004-10-19 |
Lek Pharmaceuticals D.D. |
Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
|
US20020183383A1
(en)
*
|
2001-02-27 |
2002-12-05 |
Rene Belder |
Pharmaceutical compositions
|
EP1372616A4
(de)
*
|
2001-03-27 |
2004-06-23 |
Ranbaxy Lab Ltd |
Stabile pharmazeutische pravastatin-zusammensetzung
|
US20060127474A1
(en)
*
|
2001-04-11 |
2006-06-15 |
Oskar Kalb |
Pharmaceutical compositions comprising fluvastatin
|
GB0111077D0
(en)
*
|
2001-05-04 |
2001-06-27 |
Biochemie Gmbh |
Organic compounds
|
US7642286B2
(en)
*
|
2001-06-21 |
2010-01-05 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions containing pravastatin
|
US20040180087A1
(en)
*
|
2001-06-21 |
2004-09-16 |
Boyong Li |
Stable controlled release pharmaceutical compositions containing pravastatin
|
US7838026B2
(en)
|
2001-09-28 |
2010-11-23 |
Mcneil-Ppc, Inc. |
Burst-release polymer composition and dosage forms comprising the same
|
US7122143B2
(en)
|
2001-09-28 |
2006-10-17 |
Mcneil-Ppc, Inc. |
Methods for manufacturing dosage forms
|
US7323192B2
(en)
*
|
2001-09-28 |
2008-01-29 |
Mcneil-Ppc, Inc. |
Immediate release tablet
|
EP1465605A1
(de)
|
2002-01-11 |
2004-10-13 |
Athpharma Limited |
Pravastatin zubereitungen und deren verwendung
|
EP1905431A1
(de)
*
|
2002-01-11 |
2008-04-02 |
Circ Pharma Research and Development Limited |
Pharmazeutische Pravastatin-Formulierungen und Verfahren zu ihrer Verwendung
|
EP1490029A4
(de)
*
|
2002-03-22 |
2006-02-22 |
Ranbaxy Lab Ltd |
Arzneimittelabgabesystem zur kontrollierten freisetzung von pravastatin
|
CA2480325A1
(en)
*
|
2002-04-16 |
2003-10-30 |
Merck & Co., Inc. |
Solid forms of salts with tyrosine kinase activity
|
MXPA05002095A
(es)
*
|
2002-09-03 |
2005-06-06 |
Biovail Lab Int Srl |
Formulaciones farmaceuticas de pravastatina y metodos de su uso.
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
US20060019269A1
(en)
*
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
US20040086566A1
(en)
*
|
2002-11-04 |
2004-05-06 |
Alpharma, Inc. |
Waxy matrix dosage forms
|
DE60315514T3
(de)
|
2002-12-20 |
2012-04-26 |
F. Hoffmann-La Roche Ag |
Hochdosierte ibandronat-formulierung
|
DE60323536D1
(de)
|
2002-12-20 |
2008-10-23 |
Pfizer Prod Inc |
Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
PL1603553T3
(pl)
*
|
2003-03-17 |
2012-04-30 |
Japan Tobacco Inc |
Kompozycje farmaceutyczne inhibitorów CETP
|
KR20050110017A
(ko)
*
|
2003-03-17 |
2005-11-22 |
니뽄 다바코 산교 가부시키가이샤 |
S-'2-(''1-(2-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-2-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법
|
TWI393560B
(zh)
*
|
2003-05-02 |
2013-04-21 |
Japan Tobacco Inc |
包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合
|
JP4553899B2
(ja)
|
2003-08-21 |
2010-09-29 |
メルク フロスト カナダ リミテツド |
カテプシンシステインプロテアーゼ阻害剤
|
EP2428516A1
(de)
|
2003-11-19 |
2012-03-14 |
Metabasis Therapeutics, Inc. |
Neue Phosphor enthaltende Thyromimetika
|
US8163797B2
(en)
*
|
2003-12-31 |
2012-04-24 |
Actavis Elizabeth Llc |
Method of treating with stable pravastatin formulation
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
WO2006008757A2
(en)
*
|
2004-05-05 |
2006-01-26 |
Cadila Healthcare Limited |
Stabilized pharmaceutical compositions of pravastatin
|
SG155189A1
(en)
*
|
2004-08-06 |
2009-09-30 |
Transform Pharmaceuticals Inc |
Novel fenofibrate formulations and related methods of treatment
|
US7642287B2
(en)
*
|
2004-08-06 |
2010-01-05 |
Transform Pharmaceuticals, Inc. |
Statin pharmaceutical compositions and related methods of treatment
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
CN100453116C
(zh)
*
|
2004-10-19 |
2009-01-21 |
上海中西制药有限公司 |
复方氨茶碱片剂及其制备方法
|
CA2588216A1
(en)
*
|
2004-11-22 |
2006-05-26 |
Dexcel Pharma Technologies Ltd. |
Stable atorvastatin formulations
|
KR20070085874A
(ko)
|
2004-12-09 |
2007-08-27 |
머크 앤드 캄파니 인코포레이티드 |
에스트로겐 수용체 조절제
|
EP1855674B1
(de)
|
2005-03-02 |
2014-07-16 |
Merck Sharp & Dohme Corp. |
Zusammensetzung zur hemmung von cathepsin k
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
PE20070335A1
(es)
*
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
LT2010528T
(lt)
|
2006-04-19 |
2017-12-27 |
Novartis Ag |
6-o-pakeistieji benzoksazolo junginiai bei csf-1r signalo perdavimo slopinimo būdai
|
US9744137B2
(en)
*
|
2006-08-31 |
2017-08-29 |
Supernus Pharmaceuticals, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
EP1911441A3
(de)
*
|
2006-10-11 |
2008-08-06 |
Lupin Limited |
Farbstabile pharmazeutische Dosierungsformen mit kontrollierter Freigabe von HMG-COA-Reduktase-Hemmern, die frei von Alkalisierungs- oder Pufferagenzien sind
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
ES2555066T3
(es)
|
2006-11-17 |
2015-12-28 |
Supernus Pharmaceuticals, Inc. |
Formulaciones de liberación sostenida de topiramato
|
JP4611444B2
(ja)
|
2007-01-10 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール
|
CN101679266B
(zh)
|
2007-03-01 |
2015-05-06 |
诺华股份有限公司 |
Pim激酶抑制剂及其应用方法
|
US20080249141A1
(en)
*
|
2007-04-06 |
2008-10-09 |
Palepu Nageswara R |
Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
|
US20080248115A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
AU2008254425A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
EP3103791B1
(de)
|
2007-06-27 |
2018-01-31 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino-derivate als histondeacetylase-hemmer
|
US8354446B2
(en)
|
2007-12-21 |
2013-01-15 |
Ligand Pharmaceuticals Incorporated |
Selective androgen receptor modulators (SARMs) and uses thereof
|
US20090226515A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Statin compositions
|
CN101732267B
(zh)
*
|
2008-11-14 |
2012-05-30 |
丽珠医药集团股份有限公司 |
普伐他汀钠片剂、其用途及其制备方法
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
JP5099731B1
(ja)
|
2009-10-14 |
2012-12-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
p53活性を増大する置換ピペリジン及びその使用
|
EP2584903B1
(de)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Neue heterozyklische verbindungen als erk-hemmer
|
CA2803558C
(en)
|
2010-06-30 |
2018-05-29 |
Mochida Pharmaceutical Co., Ltd. |
.omega.3 fatty acid compound preparation
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
DK2606134T3
(da)
|
2010-08-17 |
2019-07-22 |
Sirna Therapeutics Inc |
RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA)
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
US8697132B2
(en)
|
2010-12-01 |
2014-04-15 |
Shire Llc |
Capsule and powder formulations containing lanthanum compounds
|
US8263119B2
(en)
*
|
2010-12-01 |
2012-09-11 |
Shire Llc |
Capsule formulations containing lanthanum compounds
|
EP2654748B1
(de)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
EP2675440B1
(de)
|
2011-02-14 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
Cathepsin-cysteinproteasehemmer
|
WO2012141160A1
(ja)
|
2011-04-12 |
2012-10-18 |
沢井製薬株式会社 |
ピタバスタチン含有製剤及びその製造方法
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
WO2012153181A1
(en)
*
|
2011-05-11 |
2012-11-15 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
KR101466617B1
(ko)
*
|
2011-11-17 |
2014-11-28 |
한미약품 주식회사 |
오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
|
TWI636783B
(zh)
*
|
2012-04-18 |
2018-10-01 |
友霖生技醫藥股份有限公司 |
含匹伐他汀(pitavastatin)穩定配方的醫藥組合物
|
EP3358013B1
(de)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Sina-zusammensetzungen
|
RU2660429C2
(ru)
|
2012-09-28 |
2018-07-06 |
Мерк Шарп И Доум Корп. |
Новые соединения, которые являются ингибиторами erk
|
AU2013352568B2
(en)
|
2012-11-28 |
2019-09-19 |
Merck Sharp & Dohme Llc |
Compositions and methods for treating cancer
|
ES2707305T3
(es)
|
2012-12-20 |
2019-04-03 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de HDM2
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
IN2013MU02470A
(de)
*
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US9458181B2
(en)
|
2013-10-08 |
2016-10-04 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
EP3094323A4
(de)
|
2014-01-17 |
2017-10-11 |
Ligand Pharmaceuticals Incorporated |
Verfahren und zusammensetzungen zur modulierung von hormonspiegeln
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
US10413543B2
(en)
*
|
2015-09-01 |
2019-09-17 |
Sun Pharma Advanced Research Company Ltd. |
Stable multiparticulate pharmaceutical composition of rosuvastatin
|
EP3706742B1
(de)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3833667B1
(de)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|
EP4077282A4
(de)
|
2019-12-17 |
2023-11-08 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|